Spago Nanomedical Strengthens Management with Head of CMC & Supply
LUND, SWEDEN / ACCESSWIRE / April 16, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced the appointment of Birgitta Rembratt Svensson as Head of CMC & Supply. Birgitta, an experienced CMC project manager with several leading positions at development and commercial stage pharmaceutical companies, will join Spago Nanomedical on June 1 and serve as a member of the management team.
"I am very pleased to welcome Birgitta to Spago Nanomedical. As Head of CMC & Supply, Birgitta's broad managerial and technical experience in regulatory CMC and pharmaceutical development, both clinical and non-clinical, will be of great importance in advancing our pipeline. Her experience from managing contract manufacturers, ensuring all operations meet delivery and quality standards, will also play an important role as we take our lead program Tumorad into the next phase," said Mats Hansen, CEO of Spago Nanomedical.
Birgitta joins from the Danish commercial stage pharmaceutical company MC2 Therapeutics where she was CMC Project Manager since 2021. Previous positions include e.g. Head of Development at Sever Pharma Solutions AB and Bioglan AB, respectively. Birgitta holds a Ph. D. in physical chemistry and a M. Sc. in chemistry from Lund University.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise treatment and diagnosis of cancer and other debilitating diseases. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company.
Attachments
Spago Nanomedical strengthens management with Head of CMC & Supply
SOURCE: Spago Nanomedical
View the original press release on accesswire.com
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
This 5-Star Stock With a Dividend Yield That Tops 4% Is a Buy
-
After Earnings, Is Target Stock a Buy, Sell, or Fairly Valued?
-
Obesity Drug Stocks: Where to Invest Now
-
How to Invest Like Warren Buffett
-
DuPont Split Gives Investors Better Choices
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?